IRIS
GATTEI, VALTER
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 268
NA - Nord America 200
AS - Asia 76
Totale 544
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 199
IE - Irlanda 108
SE - Svezia 59
DE - Germania 38
IT - Italia 33
IN - India 29
SG - Singapore 20
UA - Ucraina 20
HK - Hong Kong 16
CN - Cina 10
CZ - Repubblica Ceca 3
FI - Finlandia 2
FR - Francia 2
CA - Canada 1
GB - Regno Unito 1
GE - Georgia 1
GR - Grecia 1
LT - Lituania 1
Totale 544
Salva come PNG Salva come JPEG
Città #
Dublin 108
Jacksonville 41
Hong Kong 16
Boardman 15
Piemonte 15
Lawrence 14
Princeton 14
Singapore 14
Chandler 12
Dearborn 12
Bremen 8
Beijing 7
Milan 5
Wilmington 5
Ann Arbor 4
Somaglia 4
Brno 3
Grafing 3
Gunzenhausen 3
Palermo 3
San Mateo 3
Helsinki 2
Norwalk 2
Novara 2
Ashburn 1
Athens 1
Fremont 1
Guangzhou 1
Hangzhou 1
Hefei 1
Houston 1
Hyderabad 1
Munich 1
Redwood City 1
Sacramento 1
Santa Clara 1
Vilnius 1
Viterbo 1
Winnipeg 1
Totale 330
Salva come PNG Salva come JPEG
Nome #
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 71
Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia 53
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 51
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 48
Mutations in the 3′ untranslated region of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia 47
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression 47
NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways 44
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 33
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 32
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 31
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 26
Elastin MIcrofibriL INterfacer1 (EMILIN-1) is an alternative prosurvival VLA-4 ligand in chronic lymphocytic leukemia 24
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 24
Quality assessment for PCR-based minimal residual disease in Lymphoma: 10 Years of cross-laboratory standardization process within the fondazione italiana linfomi MRD network 23
XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling 8
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial 3
Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real‐World” study 3
Totale 568
Salva come PNG Salva come JPEG
Categoria #
all - tutte 4.258
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.258
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202091 0 0 0 0 8 7 11 1 7 46 10 1
2020/202154 8 0 8 0 8 3 8 0 8 3 8 0
2021/202257 0 0 3 4 5 0 3 0 4 2 14 22
2022/2023212 15 13 17 0 10 15 7 15 109 1 3 7
2023/2024106 8 13 9 6 13 1 16 0 0 0 10 30
2024/202523 7 0 9 2 5 0 0 0 0 0 0 0
Totale 568